📊 AYTU Key Takeaways
Investment Thesis
AYTU BioPharma faces severe profitability challenges with a -29.7% net margin and negative operating income despite 64.7% gross margins, indicating significant operational inefficiencies or high R&D/SG&A costs. While the company maintains adequate liquidity with $30M cash and positive free cash flow of $3M, the persistent losses combined with negative ROE (-60.7%) and ROA (-7.1%) suggest the current business model is not generating value for shareholders. The marginal 1.8% revenue growth fails to offset deteriorating bottom-line performance, raising sustainability concerns.
AYTU Strengths
- Strong gross margin of 64.7% indicates solid pricing power and product-market fit at the production level
- Positive operating cash flow of $3.1M and free cash flow of $10.5M FCF margin provide near-term liquidity runway
- Adequate cash position of $30M with current ratio of 1.16x supports short-term operational needs
- Manageable debt/equity ratio of 0.70x indicates reasonable leverage levels
AYTU Risks
- Persistent net losses (-$8.6M) and negative operating margins (-12%) demonstrate the company is destroying shareholder value operationally
- Severely negative ROE (-60.7%) indicates equity is being eroded; current equity of $14.2M is inadequate relative to $122M asset base
- Minimal revenue growth of 1.8% YoY insufficient to achieve profitability or scale; company may lack competitive momentum
- Negative interest coverage ratio (-1.7x) indicates inability to service debt from operating earnings; reliant on cash reserves
- Zero insider trading activity in last 90 days may suggest lack of confidence from management
Key Metrics to Watch
- Operating margin trend - critical to assess if company can reach profitability
- Quarterly revenue growth rate - currently anemic at 1.8% YoY
- Cash burn rate and cash runway - $30M cash must sustain operations if losses continue
- Gross margin sustainability - verify 64.7% margin is maintained as revenue scales
- R&D efficiency and pipeline progress - understand why operating costs exceed gross profit
AYTU Financial Metrics
💡 AI Analyst Insight
AYTU BIOPHARMA, INC presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AYTU Profitability Ratios
AYTU vs Healthcare Sector
How AYTU BIOPHARMA, INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AYTU Balance Sheet & Liquidity
AYTU 5-Year Financial Trend
5-Year Trend Summary: AYTU BIOPHARMA, INC's revenue has shown modest growth of 1% over the 5-year period. The most recent EPS of $-74.01 indicates the company is currently unprofitable.
AYTU Growth Metrics (YoY)
AYTU Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $15.2M | $788.0K | $-0.26 |
| Q1 2026 | $13.9M | $1.5M | $-0.08 |
| Q3 2025 | $14.0M | -$220.0K | $0.21 |
| Q2 2025 | $16.2M | -$220.0K | $-0.04 |
| Q1 2025 | $16.6M | $1.5M | $-0.15 |
| Q3 2024 | $18.0M | -$220.0K | N/A |
| Q2 2024 | $22.9M | -$220.0K | N/A |
| Q1 2024 | $22.1M | -$701.0K | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AYTU Capital Allocation
AYTU SEC Filings
Access official SEC EDGAR filings for AYTU BIOPHARMA, INC (CIK: 0001385818)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AYTU
What is the AI rating for AYTU?
AYTU BIOPHARMA, INC (AYTU) has an AI rating of SELL with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AYTU's key strengths?
Strong gross margin of 64.7% indicates solid pricing power and product-market fit at the production level. Positive operating cash flow of $3.1M and free cash flow of $10.5M FCF margin provide near-term liquidity runway.
What are the risks of investing in AYTU?
Persistent net losses (-$8.6M) and negative operating margins (-12%) demonstrate the company is destroying shareholder value operationally. Severely negative ROE (-60.7%) indicates equity is being eroded; current equity of $14.2M is inadequate relative to $122M asset base.
What is AYTU's revenue and growth?
AYTU BIOPHARMA, INC reported revenue of $29.1M.
Does AYTU pay dividends?
AYTU BIOPHARMA, INC does not currently pay dividends.
Where can I find AYTU SEC filings?
Official SEC filings for AYTU BIOPHARMA, INC (CIK: 0001385818) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AYTU's EPS?
AYTU BIOPHARMA, INC has a diluted EPS of $-0.89.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.